Research Evidence Comparison# CagriSema Research# The REDEFINE Phase 3 program provides robust evidence: REDEFINE 1 (3,417 participants, 20.4% weight loss at 68 weeks) and REDEFINE 2 (1,200 T2D participants, 13.7% weight loss)
The self-controlled time series design removes time constant confounders [26], therefore we did not adjust for them in the analysis
The trial was preregistered at ClinicalTrials.gov (NCT06309667) on February 14, 2024, and conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines
What are ways to deal with the side effects of GLP-1
This dual mechanism is why tirzepatide consistently outperforms every other weight loss medication in head-to-head clinical evidence
Hydration Dehydration worsens nausea significantly Sip water throughout day (not large amounts at once) Aim for 810 glasses daily Electrolyte drinks if experiencing diarrhea 5